When Should a Biotech or Life Science Company Hire a Fractional CBO or CSO? Five Signs It's Time
Hiring a full-time Chief Business Officer or Chief Strategy Officer is a significant commitment — salary, equity, benefits, and the time and bandwidth to recruit the right person. For early- and mid-stage biotech and life science companies, a fractional executive offers the same strategic expertise and execution capacity at a fraction of the cost and without the long-term overhead. Here are five signs a fractional executive may be exactly what your organization needs to reach the next level.
1. You have a critical BD opportunity — or are actively seeking one — and no one dedicated to leading it.
A partnership, licensing deal, or investor conversation is on the table or being pursued, and you need someone who has been in that room and ecosystem before — who knows how to structure a term sheet, run a roadshow, navigate internal and external stage gate governance, and facilitate due diligence with a pharma, medtech, or TechBio counterpart.
A fractional CBO can mobilize quickly, partner with your multidisciplinary leadership team across R&D, Regulatory, Finance, Commercial, and Legal, optimize limited bandwidth, and create momentum from day one.
2. You are approaching a major strategic inflection point.
Series B fundraising, a platform pivot, a first-in-class indication, or a partnership with a multinational all require executive-level strategic clarity that a stretched leadership team often cannot provide alone. A fractional CSO partners directly with your leadership team to build the 1–3–5 year strategic plan, board presentations, and portfolio prioritization framework — delivering senior expertise precisely when and where it is needed, without the permanent overhead.
3. Your team is developing a multimodal solution and needs to activate a cross-vertical alliance.
Biotech teams think like biotech teams — and that is both a strength and a blind spot. If your next partnership requires navigating a pharma, medtech, diagnostics, or public-private counterpart, the difference in commercial logic, deal structure, and decision-making culture can cause critical opportunities and risks to get lost in translation. A fractional executive with demonstrated experience leading combined teams across multiple life science verticals can bridge those organizational and domain cultures, align workstreams, and accelerate progress that a single-vertical team would struggle to achieve alone.
4. You face a strategic leadership gap that requires urgent action — and the workload is a defined phase.
Fractional executives are available in weeks, not months. In strategic partnerships, speed and early momentum matter — a slow start signals uncertainty to potential partners and can cost you the deal, as multinationals regularly reprioritize upon shifts in their deal funnel.
A fractional CBO or CSO brings an established network, proven playbooks, and the ability to execute without a learning curve. And when the critical phase is complete — the deal closed, the strategy set, the team built — the engagement ends cleanly, without severance or transition complexity.
5. You want a clear strategic roadmap for your next level of growth or investment.
Exploratory and opportunistic partnerships are often the starting point for the most pioneering innovations in life science — but scaling them requires a sound underlying strategy and the organizational discipline to execute against it. The challenge for early-stage teams is that the higher risk profile of pioneering innovation comes with compressed bandwidth: leadership is simultaneously managing immediate operational demands and maintaining long-term roadmap discipline, with limited capacity for both.
Bringing in a fractional executive for a defined engagement of three to six months creates the conditions to move forward with clarity — on strategy, on infrastructure, and on organizational readiness — before locking in permanent leadership decisions. It is low-risk, high-return diligence on your own strategy.
Beyond the five signs above, there is a sixth pattern worth naming — one that shows up repeatedly in early-stage organizations and is often the hardest to self-diagnose.
Your partnering approach has limited conversion — and you're not sure why.
Early-stage life science organizations often fall into one of two strategic traps that a fractional executive can address while managing limited internal resources.
The first is attempting to boil the ocean. Tech platforms with broad therapeutic or commercial applications are genuinely exciting — but the instinct to maximize optionality in a partnering conversation often produces the opposite of the intended effect. What feels like demonstrating range reads to a seasoned pharma or medtech counterpart as the absence of a point of view. Getting to the right conversation requires knowing which door to knock on first — and why.
The second is a pitch that reads as thorough but generates little traction. Early-stage organizations invest enormous effort in roadshow materials — and the decks are often genuinely impressive. What reads internally as optionality, however, often reads externally as limited strategic conviction — and seasoned BD counterparts at pharma and medtech companies recognize that distinction immediately. There is a meaningful difference between a presentation that captures what an organization has built and one that compels a partner to champion it through their next internal pipeline review and clear a governance threshold. That gap is rarely visible from the inside.
Forest & Weeds works with life science organizations at exactly these inflection points — where interim senior bandwidth to pivot, partner, and strategically advance becomes essential for effective growth. Contact us to explore whether a fractional engagement is the right fit.
